stars 1 stars 2 stars 3

InnoCan Pharma is a pharmaceutical company specializing in developing novel therapeutics that harness the unique healing properties of Cannabinoids to improve quality of life. OUR ADVANTAGES Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel’s worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results. EXPECTED EARLY REVENUES: InnoCan expects to generate early revenues ($30 million in 5 years) from the multi-billion dollar Over The Counter (OTC) market by leveraging the rapid FDA OTC drug monograph process or similar regulatory pathways in Europe and Canada. These regulatory pathways enable InnoCan, in a very short time, to bring to market outstanding new products that combine the huge therapeutic potential of Cannabinoid complex/hemp oil added “excipients” to existing approved OTC drugs. TECHNOLOGY: POWERFUL, PATENT PENDING FORMULAS WITH SMART DELIVERY SYSTEMS InnoCan's products will be highly differentiated within the market through the powerful synergistic effect of the Cannabis-complex Hemp Oil with the active ingredients, combined with our on-demand release delivery system providing improved patient efficacy and compliance. FIRST-LINE PRODUCTS: A LEAP-FORWARD IN DERMATOLOGY TREATMENT DESIGN The companies first products will initially target the multi-billion dollars markets of psoriasis and localized pain , where research shows topical cannabinoid-combined treatments are highly effective, followed by oral hygiene, eczema/ itching, skin support after chemotherapy and women's health. To join the investment opportunity with InnoCan, please contact Iris Bincovich at IrisB@InnocanPharma.com.

View Top Employees from InnoCan Pharma
Website http://innocanpharma.com/
Revenue $2 million
Employees 14 (11 on RocketReach)
Founded 2017
Phone +972 54-471-1171
Technologies
Industry Pharmaceutical Manufacturing, Drug Stores & Pharmacies, Pharmaceutical, Pharmaceuticals, Retail, Health Care
SIC SIC Code 28 Companies, SIC Code 283 Companies
NAICS NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies

InnoCan Pharma Questions

The InnoCan Pharma annual revenue was $2 million in 2024.

Nelson Halpern is the CFO of InnoCan Pharma.

11 people are employed at InnoCan Pharma.

The NAICS codes for InnoCan Pharma are [3254, 325, 32, 32541].

The SIC codes for InnoCan Pharma are [28, 283].

Top InnoCan Pharma Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
talentculture2022
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users